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SHORT COMMUNICATION
Preliminary findings on the expression ofthymosin beta-10 in human breast
cancer
S Verghese-Nikolakakil, N Apostolikas2, E Livanioul, DS Ithakissios3 and GP Evangelatos1
'Institute of Radioisotopes and Radiodiagnostic Products, NCSR 'Demokritos', 153 10 Athens, Greece; 2Department of
Histopathology, Hellenic Anticancer Institute, St Savas Hospital, 171 Alexandra Avenue, 115 22 Athens, Greece; 3Department of
Pharmacy, University ofPatras, 261 10 Patras, Greece.
Summary Paraffin sections from 30 human breast tissue specimens were stained with a specific antibody for
thymosin beta-10, ATBIO(38-43). The results showed that thymosin beta-10 was detected mainly in the
malignant tissue, particularly in the cancerous cells, whereas the normal cell population around the lesions
showed very weak staining. Also, the intensity of staining in the cancerous cells was proportionally increased
with the increasing grade of the lesions.
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Thymosin beta-lO belongs to a family of highly conserved
peptides and consists of 43 amino acids with a molecular
weight of approximately 4.8 kDa (Hannappel et al., 1982).
In most mammalian species studied so far, two beta-
thymosins have been found, and in humans and rats
thymosin beta-10 is accompanied by thymosin beta-4, a
related protein with 85% structural homology (Erickson-
Viitanen et al., 1983a,b). Even though thymosin beta-4 and
thymosin beta-10 were first isolated in the immune system
(Horecker and Morgan, 1984), their mRNAs have been
detected in most tissues (Lin and Morrison-Bogorad, 1990),
where thymosin beta-4 occurs in significantly larger
quantities than thymosin beta-10 (Hall et al., 1991).
According to recent reports, both these thymosins are G-
actin-binding proteins in most cell types (Cassimeris et al.,
1992; Yu et al., 1993), and in this manner are believed to
play important roles in the functions of the cytoskeleton, of
which actin is a crucial component (Yu et al., 1994). In spite
of their structural and functional similarities, different
expression patterns have been observed for thymosin beta-
4 and thymosin beta-10. For example, while both thymosins
are strongly expressed in fetal brain and other fetal organs,
thymosin beta-10 levels fall considerably in most adult
tissues (Lin and Morrison-Bogorad, 1990; Hall et al., 1990,
1991). Lately, their possible association with cancer has
aroused interest in this class of peptides. The expression of
thymosin beta-10 mRNA was found to be increased in renal
cell carcinoma and other types of tumour in comparison
with normal tissue (Hall, 1991a), while other workers have
reported that expression of thymosin beta-10 mRNA was
associated with metastatic behaviour of human melanoma
cell lines in nude mice (Weterman et al., 1993). Even though
the exact molecular mechanism by which thymosin beta-10
may function is unclear, a number of reports present to date
support its significant participation in cellular functions with
some evidence for its participation in carcinogenesis (see
Hall, 1994 for review).
Expression levels of the thymosin beta-10 protein have not
been studied sufficiently, except for one report by Hall et al.
(199la) that indicated increased concentrations in tissue
extracts using high-performance liquid chromatography
(HPLC). In order to investigate and clarify the role of
thymosins as potential tumour markers, our laboratory has
undertaken research to develop reliable detection assays that
are sensitive, reproducible, fast and simple enough for routine
use. For this purpose, we produced a specific antibody
against the selected carboxy-terminal hexapeptide fragment of
thymosin beta-10, the region least homologous with thymosin
beta-4, the other beta-thymosin in humans (Goodall and
Horecker, 1987), and adopted an immunohistochemical
technique capable of detecting thymosin beta-10 in human
specimens in its natural surroundings.
In this paper, we announce very interesting preliminary
findings of this immunohistological study on paraffin sections
of human breast cancer.
Materials and methods
Primary antibody
The primary antibody, ATB1O(38-43), was produced against
the carboxy-terminal peptide fragment (amino acids 38-43),
which was prepared using a solid-phase synthesis method
(Leondiadis et al., 1996a). In brief, a New Zealand white
rabbit was immunised with the peptide-keyhole limpet
haemocyanin (KLH) conjugate emulsified with complete
Freund's adjuvant. The first booster dose was given 6 weeks
after immunisation, followed by subsequent doses every 4
weeks. The antiserum which was collected 10- 12 days after
each booster injection was checked for specificity and titre,
aliquoted and stored at -35°C until use. The antiserum used
in this study was obtained after the third booster dose.
Clinical material
Twenty-five breast tissue samples were collected from female
patients aged between 24 and 76 years after they had been
examined in the Histopathology Department of the Anti-
cancer Institute at the St Savas Hospital, Athens. Each
specimen was fixed in 20% formalin, embedded in paraffin
and stored until use.
Histopathologically, breast cancer lesions may be broadly
divided into two classes: (1) ductal carcinoma, which
comprises 90% of the detected cases; and (2) lobular
carcinoma. Both classes may further consist of in situ-type
lesions or infiltrating lesions. The infiltrating lesions of
ductal carcinoma, which happen to form the major part of
the clinical material included in this study, may be of non-
special type or of special type: tubular, myeloid, papillary,
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Table I Classification of breast tissue samples
No. of
Diagnosis cases
Negative (non-neoplastic breast lesions) 4
Typical hyperplasia of duct epithelium I
Fibroadenomas 2
In situ ductal carcinomas 2
In situ and infiltrating carcinomas 3
Infiltrating ductal carcinomas
Special type (tubular) gradel I
Non-special type gradeII 10
Non-special type grade III 2
mucinoid, etc. depending on the characteristics of the
lesions. Depending on the diagnosis, the samples were
classified as shown in Table I.
Immunohistochemistry
Sections (5 ,um) were cut from the paraffin blocks and mounted
on glass microslides for immunohistological staining. They
were dewaxed at 56-60°C for 20 min, followed by two serial
incubations in xylene for 5 min each, after which they were
rehydrated by passing through a graded series of alcohol and
watermixtures, and finally water. After rinsingwith phosphate-
buffered saline (PBS) pH 7.2, they were soaked for 15 min in
3% hydrogen peroxide to block any endogenous peroxidase,
followed by normal goat serum at 1:5 dilution. The sections
were incubated with the primary antibody (1:100) for 1 h and,
subsequently, after washing, with horseradish peroxidase-
labelled goat anti-rabbit IgG (1:100) for 20 min. Finally, the
slides were immersed in di-amino benzidine-HCl (tablets,
Sigma) solution for colour development, and counterstained
with Harry's haematoxylin. Positive reactions were scored as
+, + + or + + + depending on an estimation of the
percentage of tumour cells staining positive and the overall
intensity of the staining reaction.
Results
In vitro enzyme-linked immunosorbent assay (ELISA) studies
showed that the antibody had a titre of 1:5000 and did not
cross-react with thymosin beta-4 (Leondiadis et al., 1996b). A
search into the databank (BLITZ Server) also revealed that
the amino acid sequence of the hexapeptide antigen used for
immunisation was not present in any other known human
protein.
As indicated by the immunohistochemical reactions,
staining with ATBIO(38-43) was mainly cytoplasmic (Figure
1) and found primarily in the neoplastic cells within the
malignantlesions, while the surrounding normal cells were very
weakly stained or not stained at all. In particular, there was
moderate to strong positivity (+ +/+ + +) in the specimens
with non-special type invasive ductal carcinomas (Figure 1) and
in situ carcinoma (Figure 2). The two specimens with grade III
lesions ofmyeloid carcinoma also showed strong positivity for
thymosin beta-10 (+ + +, Figure 3), whereas the one specimen
with tubular carcinoma in grade I was comparatively less
positive (+, Figure 4). On the other hand, the hyperplastic and
Figure 2 (a) Paraffin section of in situ breast cancer stained with
ATBIO(38-43) showing increased expression of thymosin beta-10
in comparison with the neighbouring normal ducts. Original
magnification x 25. (b) Higher magnification of in situ breast
cancer stained with ATB10(38 -43). Original magnification x 200.
Figure 1 Paraffin section of infiltrating carcinoma (grade II), Figure 3 Paraffin section of myeloid carcinoma of the breast
non-special type, of the human breast showing cytoplasmic stained for thymosin beta-10. Note strong positivity of grade III
expression of thymosin beta-10. Original magnification x400. cancer cells in the lesion. Original magnification x 100.Thymosin beta-10 expression in breast cancer
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Figure 4 Paraffin section of tubular carcinoma (grade I) of the
breast stained for thymosin beta-10. Low amount of thymosin is
locally expressed by the cells in the carcinoma. Original
magnification x400.
premalignant lesions showed weak staining (+), while the
benign neoplastic lesions were barely positive for thymosin
beta-10 (Figure 5). In control experiments in which non-
immune rabbit serum was used as the primary antibody, no
positive reaction was noticed on the sections. The staining
pattern ofthe specimens is summarised in Table II.
In other words, the intensity of staining with the
ATB1O(38-43) antibody in the malignant lesions presented
the following trend: negative breast lesion (-)--+benign
neoplasia (+/-)-+typical ductal hyperplasia (+)-+cancer in
situ (+ +/+ + +)--grade I carcinoma (+)--grade II
carcinoma (+ +/+ + +)--grade III carcinoma (++ +).
Discussion
The results of this blind study show two important aspects of
thymosin beta-10 that could come into use for diagnosis and
prognosis of breast cancer patients.
Firstly, in all cases that were tested, thymosin beta-10 was
highly expressed in the neoplastic cells of human breast
cancer when compared with the normal cell population
present in the uninvolved tissue. The weak staining of normal
tissue was not surprising, because minute amounts of
thymosin beta-10 are present in normal human tissue (Hall,
1991a). However, the distinct staining of cancerous lesions
against a relatively weak background using immunohistolo-
gical methods could be an advantage during histopathologi-
cal diagnosis of breast cancer. This was particularly evident
in in situ ductal carcinoma in which only one particular
mammary duct was affected, showing increased thymosin
beta-10 expression in comparison with the rest of the tissue
(Figure 2).
Secondly, increased expression of thymosin beta-10 was
found to be associated with rising grade and, therefore,
reduced differentiation of the cells in the cancerous tissue.
For example, in tubular ductal carcinoma in grade I (Figure
4), there was much lower expression than in myeloid





Figure 5 Paraffin section of fibroadenoma of the breast stained
for thymosin beta-10. Note lack of staining in the fibroblasts and
weakly positive staining of the epithelium. Original magnifica-
tion x 200.
Table II Pattern of thymosin beta-10 expression in the clinical
specimens
Positivityfor
Diagnosis No. of cases thymosin beta-lOa
Negative 4 3 (-) 1(+I -)
Hyperplasia 1 1 (+)
Fibroadenoma 1 1 (+/-)
In situ 2 2(+ ++)
In situ and infiltrating 3 3 (+ ++)+++ +)
Infiltrating grade I 1 1 (+)
Infiltrating gradeII 10 10 (+ ++)+++ +)
Infiltrating gradeIII 2 2 (+ + +)
a_, negative; +, weakly positive; + +, moderately positive;
+ + +, strongly positive.
addition of a morphogen, such as all-trans retinoic acid,
modulates thymosin beta-10 expression depending on the
type ofcell line used (Hall et al., 1990; Hall, 1991b), indicates
some association cell differentiation might have on thymosin
beta-10 expression or vice versa. Similarly, increased
thymosin beta-10 mRNA was found in immature rat ovaries
treated with human chorionic gonadotropin (Hall et al.,
1991). More work will, however, be needed to clarify further
the effect of the state of differentiation on thymosin beta-10
expression in cells and tissues.
The number of patients included in this study limits firm
conclusions at present and it is being extended to a larger
number of specimens that are expected to provide
statistically significant answers. Even so, this preliminary
study provides sufficient indication that its high expression
in malignant breast tissue and its association with cancer
grade could make thymosin beta-10 of potential diagnostic
value. It seems that its detection with a specific antibody,
such as ATB1O (38-43) with a routinely used technique,
such as immunohistochemistry on paraffin-fixed sections,
could contribute immensely during diagnosis and even
prognosis of human breast cancer.
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